24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Medical Disorders
Resources
Basic InformationLookupsLatest News
AHA News: How Bacteria in Your Gut Interact With the Mind and BodyMusic Might Help Soothe Ailing HeartsCould an Injected Electrode Control Your Pain Without Drugs?100,000 Dead, 40 Million Unemployed: America Hits Grim Pandemic MilestonesFDA Approves IV Artesunate for Severe Malaria'Silent' COVID-19 More Widespread Than ThoughtDrug Combos May Be Advance Against Heart FailurePollen Fragments Linger After Rains, Leaving Allergy Sufferers MiserableA New Hip or Knee Can Do a Marriage Good, Study FindsOnly Half of Americans Say They'd Get a Coronavirus Vaccine: SurveyAlzheimer's Gene Linked to Severe COVID-19 RiskCoronavirus Cases Ticking Upwards in Nearly a Dozen U.S. StatesLockdown Got You Down? Experts Offer Tips to De-StressCould a Hormone Help Spur High Blood Pressure?Nursing Homes Are Ground Zero for COVID-19Getting Back to Work Safely After LockdownRemdesivir Will Not Be Enough to Curb COVID-19, Study FindsOutdoor Swimming Pools Not a COVID-19 Risk: ExpertStrokes Are Deadlier When They Hit COVID-19 PatientsAHA News: How to Accurately Measure Blood Pressure at HomeU.S. Earmarks $1.2 Billion for New Vaccine Deal as Coronavirus Deaths Near 95,000During the Pandemic, How Safe Is the Great American Summer Vacation?COVID-19 Damages Lungs Differently From the Flu: StudyMore Evidence Hydroxychloroquine Won't Help, May Harm COVID-19 PatientsYour Sleep Habits May Worsen Your AsthmaExtra Pounds Could Bring More Painful JointsCOVID Can Complicate Pregnancy, Especially If Mom Is ObeseWHO Predicts COVID-19 Will Take Heavy Toll in AfricaCombining Remdesivir With Other Meds Could Boost COVID-Fighting PowerMultiple Sclerosis Ups Odds for Heart Trouble, StrokeAHA News: Not Wanting to Burden Busy Hospitals, She Disregarded Heart Attack SignsExperimental Vaccines Shield Monkeys From CoronavirusHeart Attack Cases at ERs Fall by Half – Are COVID Fears to Blame?Asthma Ups Ventilator Needs of Younger Adults With COVID-19: Study1 in 5 Hospitalized NYC COVID-19 Patients Needed ICU CareObesity Ups Odds for Dangerous Lung Clots in COVID-19 PatientsDoes 6 Feet Provide Enough COVID Protection?COVID-19 Antibodies May Tame Inflammatory Condition in Kids: StudyAs Americans Return to Work, How Will COVID Change the Workplace?COVID and Hypochondria: Online Therapy May Help Ease FearsAHA News: Is High Blood Pressure Inevitable?People Mount Strong Immune Responses to Coronavirus, Boding Well for a VaccineProms Gone, Graduations Online: Pandemic Cancels Kids' Rites of PassageDon't Delay If Cancer Symptoms Appear – Call Your DoctorPulmonary Rehab Can Help People With COPD, So Why Do So Few Get It?COVID-19 Will Delay 28 Million Elective Surgeries Worldwide: StudyMost U.S. States Reopening as Coronavirus Cases DeclineRate of New U.S. Coronavirus Cases Is DecliningCould Certain Chemicals Trigger Celiac Disease?Poor Americans Likely to Miss Preventive Heart Screenings: Study
Questions and AnswersLinks
Related Topics

Diabetes

Is That Statin Doing You Any Good?

HealthDay News
by -- Robert Preidt
Updated: Oct 17th 2019

new article illustration

THURSDAY, Oct. 17, 2019 (HealthDay News) -- Many people who take cholesterol-lowering statins may not benefit from them, researchers say.

Drugs like atorvastatin (Lipitor) and fluvastatin (Lescol) provide little value to people without heart disease, new research shows. Yet these heart-healthy folks represent a sizable number of statin users.

While statins for people with heart disease isn't controversial, their use in people without heart disease (known as "primary prevention") is the subject of debate.

The use of statins for primary prevention "warrants more careful consideration," concluded researchers led by Paula Byrne of the National University of Ireland Galway.

Used in this way, statins "may be an example of low value care and, in some cases, represent a waste of health care resources," the study authors said.

Changes in clinical guidelines have increased the number of people eligible to take statins. In many countries, the majority of people taking the drugs do so for primary prevention.

For the study, Byrne's team analyzed data from Ireland from 1987 through 2016. The investigators found that the proportion of adults older than 50 eligible for statins rose from 8% under 1987 guidelines to 61% under 2016 guidelines. That means a far greater number of lower-risk people became eligible for statin treatment.

The number of people who would need to be treated with statins to prevent one major cardiovascular event also increased substantially, from 40 at the lowest risk under 1987 guidelines to 400 at the lowest risk under 2016 guidelines.

As part of the study, the investigators also analyzed primary prevention data for people with an average age of 62 to 69, who were taking statins for one to five years.

Overall, there were significant reductions in death from any cause, cardiovascular deaths, and major coronary or cardiovascular events. However, when the baseline risk of developing heart disease was taken into account, most outcomes were not statistically significant, "raising uncertainty about the benefits of statins for primary prevention," Byrne and her colleagues wrote.

The findings showed that none of the people classified as low or moderate risk in primary prevention would achieve acceptable levels of risk reduction to justify taking a daily statin. The results were published Oct. 16 in the BMJ.

"We need to assess and understand the evidence underlying these trends," the study authors wrote in a journal news release.

Statins are one of the most commonly used medicines worldwide, with sales estimated to approach $1 trillion by 2020. But important clinical trial data on statins is not available for independent analysis, the researchers noted.

More information

The American Heart Association has more on cholesterol-lowering drugs.